CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: August 4, 2015
Result type: Reports
Project Number: SR0447-000
Product Line: Reimbursement Review

Generic Name: Sacubitril/valsartan

Brand Name: Entresto

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Therapeutic Area: Heart failure, NYHA class II or III

Indications: Heart failure, NYHA class II or III

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: March 18, 2016

Recommendation Type: List with clinical criteria and/or conditions

Request for Resubmission: Eligible (January 6, 2020)